


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-220) CASIMERSEN
 PRONUNCIATION kas" i mer' sen
 THERAPEUTIC CLAIM Treatment of Duchenne Muscular dystrophy

CHEMICAL NAMES

1. RNA, [*P*-deoxy-*P*-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-A-A-m⁵U-G-C-C-A-m⁵U-C-C-m⁵U-G-G-A-G-m⁵U-m⁵U-C-C-m⁵U-G), 5'-[*P*-[4-[[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]carbonyl]-1-piperazinyl]-*N,N*-dimethylphosphonamidate]
1. all-*P*-ambo-[2',3'-azanediy]-*P*-(dimethylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G) 5'-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N,N*-dimethylphosphonamidate}

STRUCTURAL FORMULA



MOLECULAR FORMULA C₂₆₈H₄₂₄N₁₂₄O₉₅P₂₂
 MOLECULAR WEIGHT 7584
 TRADEMARK None as yet
 SPONSOR Sarepta Therapeutics, Inc.
 CODE DESIGNATIONS SRP-4045
 CAS REGISTRY NUMBER 1422958-19-7
 UNII X8UHF7SX0R
 WHO NUMBER 10354

gbk